Anthropic AI model generates 35,000 antibody designs for drug discovery. Published: Oct 28 2026, 11:01 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Anthropic's Claude AI has successfully generated 35,000 antibody designs for potential allergy treatments, demonstrating significant efficiency in drug discovery, manufacturing documentation, and clinical development research. Anthropic advances drug discovery with Claude AI. Artificial intelligence company Anthropic said its Claude model generated around 35,000 antibody designs in about a month for a potential food allergy treatment, as it expands efforts to use AI across drug discovery, manufacturing and clinical development. In an update on its life sciences research, Anthropic said its work with biotechnology company Divergence Labs produced early results for a proposed treatment designed to remove immunoglobulin E (IgE), a molecule involved in allergic reactions, from immune cells. The approach aims to go beyond standard medications that neutralise IgE circulating in the blood. Breakthroughs in allergy and cancer research. Divergence Labs identified three designs that could bind to IgE and 20 that could dislodge it from immune cells. Three of the 20 designs appeared to perform better than the standard medication at dislodging IgE, Anthropic said. The next step is to combine the two functions into a potential drug. The company said it had partnered with six organisations developing medicines and had also started its own drug discovery programmes, including research into rare childhood forms of muscular dystrophy. "We plan to scale this work up substantially from here," Anthropic said, adding that its strategy was to involve AI in multiple stages of drug development rather than focusing only on designing molecules. Advancements in oncology and clinical planning. In another project, Claude helped Generate Biomedicines develop a shorter version of genetic instructions used in CAR T-cell therapy, which is being explored for treating solid tumours. One design was around 70 per cent shorter than the standard version and, in laboratory tests, enabled immune cells to produce roughly 10 times as many receptors and kill tumour cells more efficiently, Anthropic said. At Enveda, Claude reviewed 1,061 pages of manufacturing documentation, identifying all 11 issues found by human reviewers and flagging seven additional issues. The approach reduced human review time by 89 per cent, from more than 25 hours to less than three hours. Anthropic also said its work with Bristol Myers Squibb was examining how Claude could support clinical trial planning and assess the likelihood of trials succeeding. The companies plan to expand this work in 2027. However, Anthropic cautioned that the research remains at an early stage and is mostly preclinical, meaning the potential medicines have generally not yet reached human testing. The company said it plans to work with more biotechnology organisations and integrate Claude further into drug development as the programmes advance. (Except for the headline, this story has not been edited by Asianetnews Editorial staff and is published from a syndicated feed.) Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Anthropic Claude Life Sciences research and drug development progress. October 27, 2026 · gemini-3.1-flash-lite Accelerating drug development with AI. Anthropic's life sciences team has spent recent months partnering with six biotechnology organizations - BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group - to integrate Claude into the drug development pipeline. The goal is to address bottlenecks across the entire lifecycle of medicine creation, including target identification, molecule design, manufacturing optimization, and regulatory filing. Key case studies in ai-driven discovery. * Generate Biomedicines: Scientists used Claude to redesign a signaling domain for CAR T-cell therapy. The resulting design was 70% shorter than the standard version while increasing receptor expression by 10x, potentially enabling more effective treatment for solid tumors. * Divergence Labs: Claude autonomously generated roughly 35,000 antibody designs to target food allergies. The model identified "hits" that dislodged IgE from immune cells more effectively than current FDA-approved medications, with the entire design process taking weeks rather than months. * BigHat Biosciences: In a lead optimization project, Claude helped refine two antibody fragments. The final variants showed significant improvements in binding affinity (10x), thermostability, and resistance to clumping. Notably, Claude helped identify that standard metrics for stability were misleading, proposing new analytical methods that were validated in the lab. * Enveda: To address the 75% of time chemists spend on paperwork, Enveda built a system connecting Claude to their manufacturing records. The model successfully flagged all issues identified by human reviewers and discovered seven additional errors, reducing total human review time by 89%. * Mithril Medicine: Acquired by Anthropic, this program demonstrated a "Pipeline-in-a-Person" model. Founder Cody Tranbarger used Claude to manage logistics across 11 external labs, taking a potential treatment for muscular dystrophy from concept to promising mouse model results in under 18 months. Industry perspectives and challenges. While these results highlight the potential for AI to streamline drug development, the community has expressed a mix of optimism and caution regarding the scope of AI's impact. * The Bottleneck Debate: Many observers note that while AI can accelerate molecule design, the most significant costs and time delays occur during clinical trials. Commenters on Hacker News emphasized that biology remains highly complex and non-deterministic compared to software engineering, meaning that "moving at the speed of life" remains a fundamental constraint. * Administrative vs. Scientific Value: Some critics argue that using AI to automate paperwork is a symptom of excessive bureaucracy rather than a breakthrough in drug discovery. However, proponents suggest that freeing scientists from administrative burdens is a necessary step to increase overall research throughput. * Access and Guardrails: Researchers have noted frustration with increasingly aggressive safety guardrails in public versions of Claude, which can impede legitimate biochemical research. Anthropic has responded by launching the Life Sciences Verification Program and providing Claude credits to researchers, though some in the academic community continue to advocate for more capable, open-source models that do not impose similar usage restrictions. Future outlook. Anthropic plans to scale these efforts, moving from preclinical research into clinical trial planning. The company is actively seeking guest investigators and partners to further test the "Pipeline-in-a-Person" model, aiming to prove that AI can enable small teams to run multiple complex drug programs in parallel, thereby reducing the financial barriers to researching rare and neglected diseases.